GB Patent

GB9226830D0 — Chemical compounds

Assigned to Celltech R&D Ltd · Expires 1993-02-17 · 33y expired

What this patent protects

Compounds of general formula (1) <IMAGE> (1) are described wherein Y is a halogen atom or a group -OR1, wherein R1 is an optionally substituted alkyl group; X is -O-, -S- or -N(R6)-, where R6 is a hydrogen atom or an alkyl group; R2 is an optionally substituted alkyl, …

USPTO Abstract

Compounds of general formula (1) <IMAGE> (1) are described wherein Y is a halogen atom or a group -OR1, wherein R1 is an optionally substituted alkyl group; X is -O-, -S- or -N(R6)-, where R6 is a hydrogen atom or an alkyl group; R2 is an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group; R3 and R4, which may be the same or different, is each a group -(CH2)nAr, where Ar is a monocyclic or bicyclic aryl group optionally containing one or more heteroatoms selected from oxygen, sulphur or nitrogen atoms and n is zero or an integer 1, 2 or 3; R5 is a hydrogen atom or an optionally substituted alkyl group; and the salts, solvates, hydrates and N-oxides. Compounds according to the invention are potent, selective and orally active PDE IV inhibitors and are useful in the prophylaxis and treatment of asthma.

Drugs covered by this patent

Patent Metadata

Patent number
GB9226830D0
Jurisdiction
GB
Classification
Expires
1993-02-17
Drug substance claim
No
Drug product claim
No
Assignee
Celltech R&D Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.